Trevor Brown Joins DCN Dx as Chief Revenue Officer to Drive Growth

DCN Dx Appoints Trevor Brown as Chief Revenue Officer

DCN Dx, a prominent in vitro diagnostics (IVD) services firm based in Carlsbad, California, has announced the appointment of Trevor Brown as its new Chief Revenue Officer. This strategic move is set to enhance the company's trajectory in diagnostics by leveraging Brown's extensive experience in the industry.

A New Era for DCN Dx

With over two decades of commercial leadership experience in diagnostics and life sciences, Brown's expertise will be pivotal in advancing DCN Dx's mission to support a diagnostic's journey from concept to market. His previous roles at renowned companies such as LASE Innovation, Luminex, and BD, underscore his proficiency in scaling teams and launching FDA- and CE-approved IVDs.

Brown's primary responsibilities at DCN Dx will encompass the development and execution of the overall commercial strategy, focusing on sales, marketing, and client development across three interconnected service areas: assay development and production, IVD-specific clinical trials and regulatory support, and biospecimen sourcing.

Leadership Insights

Expressing excitement over the new appointment, DCN Dx CEO Charlie Mamrak stated, "Trevor's deep understanding of diagnostics, coupled with his insight into the commercialization process, makes him exceptionally suited to lead our next growth phase." This sentiment highlights the significant impact Brown is expected to have on the organization moving forward.

Trevor Brown himself remarked on the motivations behind his decision to join DCN Dx, emphasizing the company's unique commitment to simplifying the pathway for partners seeking to bring innovative diagnostics to market. He noted, "Our team's extensive experience in developing assays and managing trials will enable us to accelerate the time to market for our partners effectively."

About DCN Dx

DCN Dx has been at the forefront of diagnostic solutions for over 20 years, having specialized in helping companies achieve commercial success for their diagnostic tests. The organization's operational structure encompasses three specialized sectors. Its CDMO (Contract Development and Manufacturing Organization) for immunoassays has successfully completed more than 560 programs aimed at developing and manufacturing quick, point-of-use tests in a facility certified by ISO 13485 and ISO 9001.

Additionally, the company's biospecimen collection services provide assay developers with global access to a diverse array of consented specimens necessary for clinical validation. Furthermore, their dedicated CRO (Contract Research Organization) manages clinical studies and regulatory submissions efficiently, drawing on the expertise of professionals who previously guided diagnostics through FDA and EU regulatory processes.

This comprehensive suite of services positions DCN Dx as a pivotal player for startups and established diagnostic manufacturers alike, offering tailored solutions for clients at any stage of their product journey.

Based in Carlsbad, California, DCN Dx continues to innovate and lead in the field of in vitro diagnostics, aiming to support cutting-edge diagnostic developments that enhance healthcare outcomes.

For more details, you can visit dcndx.com.